BRISTOL-MYERS SQUIBB COMPANY Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Fair Value of Plan Assets (Deprecated 2018-01-31)
BRISTOL-MYERS SQUIBB COMPANY (BMY) had Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Fair Value of Plan Assets (Deprecated 2018-01-31) of $678.00 million as of 2017-12-31, per its 10-K filed 2018-02-13.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets · last filed 2018-02-13
- 2017-12-31: Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Fair Value of Plan Assets (Deprecated 2018-01-31) $678.00M.
- 2016-12-31: Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Fair Value of Plan Assets (Deprecated 2018-01-31) $5.56B.
- 2015-12-31: Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Fair Value of Plan Assets (Deprecated 2018-01-31) $4.51B.
- 2014-12-31: Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Fair Value of Plan Assets (Deprecated 2018-01-31) $4.92B.
| Period end | Defined Benefit Plan, Plan with Benefit Obligation in Excess of Plan Assets, Fair Value of Plan Assets (Deprecated 2018-01-31) |
|---|---|
| 2017-12-31 | $678.00M 10-K · filed 2018-02-13 |
| 2016-12-31 | $5.56B 10-K · filed 2018-02-13 |
| 2015-12-31 | $4.51B 10-K · filed 2017-02-21 |
| 2014-12-31 | $4.92B 10-K · filed 2016-02-12 |
| 2013-12-31 | $732.00M 10-K · filed 2015-02-13 |
| 2012-12-31 | $6.43B 10-K · filed 2014-02-14 |
| 2011-12-31 | $5.54B 10-K · filed 2013-02-15 |
| 2010-12-31 | $5.46B 10-K · filed 2012-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |